CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2993-3002

  Wang, Xiuli ^a   Wong, Chinglam W ^a   Urak, Ryan ^a   Mardiros, Armen ^a   Budde, Lihua E ^a   Chang, Wen Chung ^a   Thomas, Sandra H ^a   Brown, Christine E ^a   La Rosa, Corinna ^a   Diamond, Don J ^a   Jensen, Michael C ^b   Nakamura, Ryotaro ^a   Zaia, John A ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CMVPP65 VACCINE; CYTOKINE; DNA; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS RECEPTOR;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DNA MODIFICATION; DRUG EFFICACY; HUMAN; IMMUNOSTIMULATION; LENTIVIRINAE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOMA; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME; VACCINATION; VIROLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; CETUXIMAB; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MICE, INBRED NOD; MICE, SCID; PHOSPHOPROTEINS; RECEPTORS, VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; VACCINATION; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942258915     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2920     Document Type: Article

References (36)

1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modifiedTcells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
4. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-recep-tor-transduced T cells. Blood 2012;119:2709-20.
5. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
6. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009;114:4283-92.
7. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immu-notherapy for posttransplantation viral infections. Biol Blood Marrow Transplant 2004;10:143-55.
8. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
9. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zetaartificialchimeric T-cell receptor for immunotherapyofHodgkin disease. Blood 2007;110:2620-30.
10. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002;99: 2009-16.
11. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-spe-cific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005;105:1622-31.
12. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122:2965-73.
13. van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001;33(Suppl 1): S32-7.
14. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006;259:219-46.
15. La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalo-virus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012;205:1294-304.
16. Pelloquin F, Lamelin JP, Lenoir GM. Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 1986;22:689-94.
17. Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE 2013;8:e82742.
18. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101:1637-44.
19. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011;118:1255-63.
20. Stastny MJ, Brown CE, Ruel C, Jensen MC. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. J Pediatr Hematol Oncol 2007;29:669-77.
21. Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid Fc receptor binding and improve T cell persistence and anti-tumor efficacy. Mol Ther 2015;23:757-68.
22. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015;3:125-35.
23. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraft-ment of human central memory-derived effector CD8+ T cells in immu-nodeficient mice. Blood 2011;117:1888-98.
24. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011;117:808-14.
25. Marchi LF, Sesti-Costa R, Ignacchiti MD, Chedraoui-Silva S, Mantovani B. In vitro activationofmouse neutrophilsbyrecombinant human interferon-gamma: increased phagocytosis and release of reactive oxygen species and pro-inflammatory cytokines. Int Immunopharmacol 2014;18:228-35.
26. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
27. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305.
28. Sun Q, Burton RL, Dai LJ, Britt WJ, Lucas KG. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 2000;165:4105-11.
29. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6.
30. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother 2004;27:405-18.
31. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lym-phoblastic leukemia. Sci Transl Med 2014;6:224ra25.
32. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011;17:5343-52.
33. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17: 1290-7.
34. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 2012;42:3174-9.
35. Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, et al. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res 2014;20: 4459-70.
36. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.